6 High-Growth Biotech Stocks Analysts Rate As Buys

|
 |  Includes: ACOR, AFFY, ALXN, ATHX, BMRN, XTNT
by: ZetaKap

Interested in gaining exposure to biotechnology companies? Do you prefer stocks that are projected to grow over the long term? Do you prefer investing in stocks that analysts have weighed in on? If so, here's a list you might be interested in.

EPS growth (earnings per share growth) illustrates the growth of earnings per share over time. The 5-Year Expected EPS Growth Rate is a long term annual growth estimate, where the growth projections are made by analysts, the company or other credible sources.

We first looked for biotechnology stocks. We next screened for businesses that have high future earnings per share growth forecasts(5-year projected EPS Growth Rate>25%). We then looked for businesses that analysts rate as "Buy" (2 < mean recommendation < 3). We did not screen out any market caps.

Do you think these stocks have strong enough fundamentals to move higher? Use our list along with your own analysis.

Bacterin International Holdings, Inc. (BONE)

Sector: Healthcare
Industry: Biotechnology
Market Cap: $69.16M
Beta: -
Click to enlarge

Bacterin International Holdings, Inc. has a 5-Year Projected Earnings Per Share Growth Rate of 26.67% and Analysts' Rating of 1.80. The short interest was 6.32% as of 05/17/2012. Bacterin International Holdings, Inc. develops, manufactures, and markets biologics products in the United States and internationally. The company's products are used in various applications, including enhancing fusion in spine surgery, relief of back pain with a facet joint stabilization, promotion of bone growth in foot and ankle surgery, promotion of skull healing, and cartilage regeneration in knee and other joint surgeries. Its biologics products include OsteoSponge, a form of demineralized bone matrix made of human bone that is used as natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC, a subchondral bone void filler and cartilage re-generation scaffold; and OsteoWrap, which wraps around non-union fractures to assist with fusion, as well as is used in conjunction with a hardware plate system.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Sector: Healthcare
Industry: Biotechnology
Market Cap: $4.45B
Beta: 1.17
Click to enlarge

BioMarin Pharmaceutical Inc. has a 5-Year Projected Earnings Per Share Growth Rate of 36.00% and Analysts' Rating of 1.70. The short interest was 9.60% as of 05/17/2012. BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. The company's commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of mucopolysaccharidosis (MPS) VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; and Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease. It develops GALNS, an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder; PEG-PAL, an enzyme substitution therapy that is under Phase II clinical trial to treat PKU; BMN-673, a Phase I/II clinical trial product for the treatment of cancer; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trials for Pompe disease, a glycogen storage disorder; and BMN-111, a peptide therapeutic that is under Phase I clinical trial for the treatment of achondroplasia.

Athersys, Inc. (NASDAQ:ATHX)

Sector: Healthcare
Industry: Biotechnology
Market Cap: $33.37M
Beta: 1.76
Click to enlarge

Athersys, Inc. has a 5-Year Projected Earnings Per Share Growth Rate of 28.00% and Analysts' Rating of 2.00. The short interest was 0.46% as of 05/17/2012. Athersys, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products in various disease areas in the United States. Its clinical development programs are focused on treating cardiovascular disease, neurological conditions, inflammatory and immune disorders, and other conditions. Its product pipeline includes MultiStem, a novel allogeneic approach to stem cell therapy and regenerative medicine for treating a range of diseases.

Affymax, Inc. (OTCPK:AFFY)

Sector: Healthcare
Industry: Biotechnology
Market Cap: $518.54M
Beta: 1.34
Click to enlarge

Affymax, Inc. has a 5-Year Projected Earnings Per Share Growth Rate of 27.50% and Analysts' Rating of 1.60. The short interest was 12.19% as of 05/17/2012. Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. It develops peginesatide (Hematide), which has completed Phase III clinical trial for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells.

Acorda Therapeutics, Inc. (NASDAQ:ACOR)

Sector: Healthcare
Industry: Biotechnology
Market Cap: $931.12M
Beta: 0.47
Click to enlarge

Acorda Therapeutics, Inc. has a 5-Year Projected Earnings Per Share Growth Rate of 30.50% and Analysts' Rating of 2.50. The short interest was 5.66% as of 05/17/2012. Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of novel therapies for multiple sclerosis (NYSE:MS), spinal cord injury (NYSE:SCI), and other central nervous system disorders primarily in the United States. Its marketed products include Ampyra (dalfampridine), a potassium channel blocker for improving walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS with walking disability under the Fampyra name internationally.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Sector: Healthcare
Industry: Biotechnology
Market Cap: $16.26B
Beta: 0.56
Click to enlarge

Alexion Pharmaceuticals, Inc. has a 5-Year Projected Earnings Per Share Growth Rate of 35.31% and Analysts' Rating of 1.80. The short interest was 1.62% as of 05/17/2012. Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the innovation, development, and commercialization of life-transforming therapeutic products for treating patients with severe and ultra-rare disorders in the United States, Europe, Latin America, Japan, and the Asia Pacific. It focuses on developing products for the treatment of diseases in the areas of hematology, nephrology, neurology, metabolic disorders, oncology, and ophthalmology. The company offers Soliris(eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder; and atypical hemolytic uremic syndrome (aHUS), an ultra-rare and life-threatening genetic disease.

Company profiles were sourced from Finviz. Financial data was sourced from Yahoo Finance.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.